Understanding the Graft-Versus-Leukaemia Reaction

References

• Barnes D. W. H., Corp M. J., Loutit J. F. and Nea I. F. E. (1956) Treatment of murine leukaemia with X-rays and homologous bone marrow. Br. Med. Jnl., 2, 626.
   PubMed Web of Science ®Google Scholar
• Dicke K. A., Van Hooft J. and Van Bekkum D. W. (1968) The selective elimination of immunologically competent cells from bone marrow and lymphatic cell mixtures. Transplantation, 6, 562–70.
   PubMed Web of Science ®Google Scholar
• Grebe S. C. and Streilein J. W. (1976) Graft versus Host reactions: a review. Adv. Immunol., 22, 119–221.
   PubMedGoogle Scholar
• Reisner Y., Kapoor N., Kirkpatrick D., Pollack M. S., Dupont B., Good R. A. and O'Reilly R. J. (1981) Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet, i, 327–31.
   Google Scholar
• Prentice H. G., Janossy G., Blacklock H. A., Bradstock K. F., Goldstein G. and Hoffbrand A. V. (1982) Use of anti-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone marrow transplantation for acute leukaemia. Lancet, i, 700–3.
   Google Scholar
• Filipovich A. H., McGlave P. B., Ramsay N. K. C., Goldstein G., Warkentin P. I. and Kesey J. H. (1982) Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host disease in allogeneic histocompatible bone-marrow transplantation. Lancet, ii, 1266–9.
   Google Scholar
• Prentice H. G., MacDonald I. D. and Hamon M. D. (1994) Understanding the mechanism of cure of acute myeloid leukaemia by allogneic bone marrow transplantation: toward the application of interleukin-2 in autologous bone marrow transplantation. J. Hematotherapy, 3, 47–50.
   PubMedGoogle Scholar
• Valentin H., Gelin C., Coulombel L., Zoccola D., Morizet J. and Bernard A. (1992) The distribution of the CDw52 molecule on blood cells and characterisation of its involvement in T cell activation. Transplantation, 54, 97–104.
   PubMed Web of Science ®Google Scholar
• Hale G. and Waldmann H. (1994) CAMPATH-1 monoclonal antibodies in bone marrow transplantation. J. Hematotherapy, 3, 15–31.
   PubMedGoogle Scholar
• Weiden P. L., Flournoy N., Thomas E. D., Prentice R., Fefer A., Buckner C. D. and Storb R. (1979) Antileukemic effect of graft-versus-host disease in human recipients of allogeneic bone marrow grafts. N. Engl. J. Med., 300, 1068–73.
   PubMed Web of Science ®Google Scholar
• Horowitz M. M., Gale R. P., Sondel P. M., Goldman J. M., Kersey J., Kolb H-J., Rimm A. A., Ringden O., Rozman C., Truitt R. L., Zwaan F. E. and Bortin M. M. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 75, 555–562.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A., van Lint M. T., Occhini D., Gualandi F., Lamparelli T., Sogno G., Tedone E., Frassoni F., Tong J. and Marmont A. M. (1991) Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood, 77, 1423–28
   PubMed Web of Science ®Google Scholar
• Collins R. H., Rogers Z. R., Bennett M., Kumar V., Nikein A. and Fay J. W. (1992) Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant, 10, 391–5.
   PubMed Web of Science ®Google Scholar
• Rassam S. M., Katz F., Chessells J. M. and Morgan G. (1993) Successful allogeneic bone marrow transplantation in juvenile CML: conditioning or graft-versus-leukaemia effect? Bone Marrow Transplant, 11, 247–50.
   PubMed Web of Science ®Google Scholar
• Mehta J., Powles R., Singhal S., Iveson T., Treleaven J. and Catovsky D. (1996) Clinical and haematological response of chronic lymphocytic and prolymphocytic leukaemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukaemia. Bone Marrow Transplant, 17, 371–5.
   PubMed Web of Science ®Google Scholar
• Slavin S., Or R., Naparstek E., Ackerstein A. and Weiss L. (1988) Cellular mediated immunotherapy of leukaemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man. Blood, 72(suppl 1), 407a.
   Google Scholar
• Kolb H-J., Mittermueller J., Clemm C., Ledderose G., Brehm G., Heim M. and Wilmanns W. (1990) Donor leukocyte transfusion for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood, 76, 2462–65.
   PubMed Web of Science ®Google Scholar
• MacKinnon S., Papadopoulos E. B., Carabasi M. H., Reich L., Collins N. H., Boulad F., Castro-Malaspina H., Childs B. H., Gillio A. P and Kernan N. A. et al. (1995) Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukaemia after bone marrow transplantation: separation of graft-versus-leukaemia responses from graft-versus-host disease. Blood, 8, 1261–8.
   Google Scholar
• Kolb H-J., Schattenberg A., Goldman J. M., Hertenstein B., Jacobsen N., Arcese W., Ljungman P., Ferrant A., Verdonck L., Neiderwieser D., Van Rhee F., Mittermueller J., De Witte T., Holler E. and Ansari H. (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood, 8, 2041–50.
   Google Scholar
• Naparstek E., Or R., Nagler A., Cividalli G., Engelhard D., Aker M., Gimon Z., Manny N., Sacks T., Tochner Z., Weiss L., Samuall S., Brautbar C., Hale G., Waldmann H. and Steinberg S. M. (1995) T-cell-depleted allogeneic bone marrow transplantation for acxute leukaemia using Campath-1 antibodies and post-transplant administration of donors peripheral blood lymphocytes for prevention of relapse. Br. J. Haematol., 89, 506–15.
   PubMed Web of Science ®Google Scholar
• Ferster A., Bujan W., Mouraux T., Devalck C., Heimann P. and Saiban E. (1994) Complete remission following donor leukocyte infusion in ALL relapsing after haploindentical bone marrow transplantation. Bone Marrow Transpl., 14, 331–2.
   PubMed Web of Science ®Google Scholar
• Prentice H. G., Sekhar M., Popat U., Deane M., Ray M., Steward B. and Lawler M. (1995) Donor leukocyte infusions for relapsed acute leukaemia post BMT. Blood, 86(suppl 1), 566a.
   Google Scholar
• Slavin S., Naparstek E., Nagler A., Ackerstein A., Kapelushnik J. and Or R. (1995) Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp. Hematol., 23, 1553–62.
   PubMed Web of Science ®Google Scholar
• Glazier A., Tutschka P. J., Farmer E. R. and Santos G. W. (1983) Graft-versus-host-disease in cyclosporine A treated rats after syngeneic and autologous bone marrow reconstitution. J. Exp. Med., 158, 1–8.
   PubMed Web of Science ®Google Scholar
• Hess A. D., Horwitz L., Beschorner W. E. and Santos G. W. (1985) Development of graft-versus-host disease-like syndrome in cyclosporine treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T-lymphocytes with apparent polyclonal anti-la specificity, including autoreactivity. J. Exp. Med., 161, 718–30.
   PubMed Web of Science ®Google Scholar
• Talbot D. C., Powles R. L., Sloane J. P., Rose J., Treleaven J., Aboud H., Helenglass G., Parikh P., Smith C., Rowley M., Cavanagh J., Milliken S., Hewitson M. and Norton J. (1990) Cyclosporine-induced graft-versus-host disease following autologous bone marrow transplantation in acute myeloid leukaemia. Bone Marrow Transpl., 6, 17–20.
   PubMed Web of Science ®Google Scholar
• Carella A. M., Gaozza E., Congiu A., Carlier P., Nati S., Truini M., Castellaneta A. and Viale M. (1991) Cyclosporine-induced graft-versus-host disease after autologous bone marrow transplantation in hematological malignancies. Annals of Hematology, 62, 156–159.
   PubMed Web of Science ®Google Scholar
• Adler A., Chervenick P. A., Whiteside T., Lotzova E. and Herberman R. B. (1988) Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukaemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood, 71, 709–716.
   PubMed Web of Science ®Google Scholar
• Gottlieb D. J., Brenner M. K., Heslop H., Bianchi A. C. M., Bello-Fernandez A. B., Mehta A. B., Newland A. C., Galazka A. R., Scott E. M., Hoffbrand A. V. and Prentice H. G. (1989) A phase 1 clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease. Br. J. Cancer, 60, 610–615.
   PubMed Web of Science ®Google Scholar
• Foa R., Meloni G., Tosti S., Novarino A., Fenu S., Gavosto F. and Mandelli F. (1991) Treatment of acute myeloid leukaemia patients with recombinant interleukin-2: A pilot study. Br. J. Haematol., 77, 491–6.
   PubMed Web of Science ®Google Scholar
• Maraninchi D., Blaise D., Viens P., Brandely M., Olive D., Lopez M., Sainty D., Marit G., Stoppa A. M., Reiffers J., Gratecos N., Bertau-Perez P., Mannoni P., Mawas C., Hercend T., Sebahoun G. and Carcassone Y. (1991) High-dose recombinant interleukin-2 and acute myeloid leukaemias in relapse. Blood, 78, 2182–7.
   PubMed Web of Science ®Google Scholar
• Lim S. H., Newland A. C., Kelsey S., Bell A., Offerman E., Rist C., Gozzard D., Bareford D., Smith M. P. and Goldstone A. H. (1992) Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia—a phase II study. Cancer Immunol. Immunother, 34, 337–42.
   PubMed Web of Science ®Google Scholar
• Hamon M. D., Prentice H. G., Gottlieb D. J., Macdonald I. D., Cunningham J. M., Smith O. P., Gilmore M., Gandhi L. and Collis C. (1993) Immunotherapy with interleukin 2 after ABMT in AML. Bone Marow Transplant, 11, 399–401.
   PubMed Web of Science ®Google Scholar
• Benyunes M. C., Massumoto C., York A., Higuchi C. M., Buckner C. D., Thomson J. A., Petersen F. B. and Fefer A. (1993) Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant, 12, 159–63.
   PubMed Web of Science ®Google Scholar
• Massumoto C., Benyunes M. C., Sale G., Beauchamp M., York A., Thompson J. A., Buckner C. D. and Fefer A. (1996) Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy. Bone Marrow Transplant, 17, 351–6.
   PubMed Web of Science ®Google Scholar
• van Lochem E., de Gast B. and Goulmy E. (1992) In vitro separation of host-specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities. Bone Marrow Transplant, 10, 181–3.
   PubMed Web of Science ®Google Scholar
• Faber L. M., van der Hoeven J., Goulmy E., Hooftman-den Otter A. L., van Luxemburg-Heijs S. A., Willemze R. and Falkenburg J. H. (1995) Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8 + or CD4 + minor histocompatibility antigen-specific cytotoxic T lymphocytes. Journal of Clinical Investigation, 96, 877–83.
   PubMed Web of Science ®Google Scholar
• de Bueger M., Bakker A., Van Rood J. J., Van der Woude F. and Goulmy E. (1992) Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J. Immunol., 149, 1788–94.
   PubMed Web of Science ®Google Scholar
• ten Bosch G. J. A., Joosten A. M., Kessler J. H., Melief C. J. M. and Leeksma O. C. (1996) Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood, 88, 3522–7.
   PubMed Web of Science ®Google Scholar
• Chen W., Peace D. J., Rovira D. K., Sheng-Guo Y. and Cheever M. A. (1992) T-cell immunity to the joining region of p210BCR-ABL protein. Proc. Nat. Acad. Sci., 89, 1468–1472.
   PubMed Web of Science ®Google Scholar
• Cullis J. O., Barrett J., Goldman J. M. and Lechler R. I. (1994) Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: studies in antigen processing defective cell lines. Leukemia, 8, 165–170.
   PubMed Web of Science ®Google Scholar
• Barrett J., Guimaraes A., Cullis J. and Goldman J. M. (1993) Immunological characterisation of the tumor-specific bcr-abl junction of Philadelphia chromosome positive chronic myeloid leukemia. Stem Cells, 11 (Suppl 3), 104–108.
   PubMed Web of Science ®Google Scholar
• Lowdell M. W., Ray N., Craston R., Corbett T., Deane M. and Prentice H. G. (1997) The in vitro detection of anti-leukaemia-specific cytotoxicity after autologous bone marrow transplantation for acute leukaemia. Bone Marrow Transplant, 19, 891–897.
   PubMed Web of Science ®Google Scholar
• Truitt R. L. and Atasoylu A. A. (1991) Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukaemia reactivity after transplantation of MHC compatible bone marrow. Bone Marrow Transplant, 8, 51–8.
   PubMed Web of Science ®Google Scholar
• Okunewick J. P., Kociban D. L., Machen L. L. and Buffo M. J. (1994) Comparison of the effects of CD3 and CD5 donor T cell depletion on graft-versus-leukaemia in a murine model for MHC-matched unrelated-donor transplantation. Bone Marrow Transplant, 13, 11–17.
   PubMed Web of Science ®Google Scholar
• Hercend T., Takvorian T., Nowill A., Tantravahi R., Moingeon P., Anderson K. C., Murray C., Bohuon C., Ythier A. and Ritz J. (1986) Characterisation of natural killer cells with anti-leukaemic activity following allogeneic bone marrow transplantation. Blood, 67, 722–8.
   PubMed Web of Science ®Google Scholar
• Rettie J. E., Gottlieb D., Heslop H., Leger O., Drexler H., Hazelhurst G., Hoffbrand A., Prentice H. G. and Brenner M. (1989) Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood, 73, 1351–8.
   PubMed Web of Science ®Google Scholar
• Korngold R. and Sprent J. (1987) Variable capacity of L3T4+ T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice. J. Exp. Med., 165, 1552–64.
   PubMed Web of Science ®Google Scholar
• Giralt S., Hester J., Huh Y., Hirsch-Ginsberg C., Rondon G., Seong D., Lee M., Gajewski J., van Bevien K. and Khouri I. (1995) CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukaemia after allogeneic bone marrow transplantation. Blood, 86, 4337–43.
   PubMed Web of Science ®Google Scholar
• Niederwieser D., Gastl G., Rumpold H., Marth C., Kraft D. and Huber C. (1987) Rapid reappearance of large granular lymphocytes (LGL) with concomitant reconstitution of natural killer (NK) activity after human bone marrow transplantation. Br. J. Haematol, 65, 301–305.
   PubMed Web of Science ®Google Scholar
• Lowdell M. W., Shamim F., Hamon M., Macdonald I. and Prentice H. G. (1995) VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation. Exp. Haematol, 23, 1530–1534.
   PubMed Web of Science ®Google Scholar
• Tratkiewicz J. A. and Szer J. (1990) Loss of natural killer activity as an indicator of relapse in acute leukaemia. Clin. Exp. Immunol., 80 241–246.
   PubMed Web of Science ®Google Scholar
• Robertson L. E., Denny A. W. and Huh Y. O. et al: (1996) Natural killer cell activity in chronic lymphocytic leukaemia patients treated with fludarabine. Cancer Chemotherapy & Pharmacology, 37, 445–50.
   PubMed Web of Science ®Google Scholar
• Kos F. J. and Engleman E. G. (1995) Requirement for natural killer cells in the induction of cytotoxic T cells. J. Immunol., 155, 578–584.
   PubMed Web of Science ®Google Scholar
• Wright A., Lee J. E., Link M. P., Smith S. D., Carroll W., Levy R., Clayberger C. and Krensky A. M. (1989) Cytotoxic T lymphocytes specific for self tumour immunoglobulin express T cell receptor gamma chain. J. Exp. Med., 169, 1557–64.
   PubMed Web of Science ®Google Scholar
• Sturm E., Braakman E., Fisch P., Vreugdenhil R. J., Sondel P. and Bolhuis R. L. H. (1990) Human V-γ9-Vδ2 T cell receptor-lymphocytes show specificity to Daudi Burkitt's lymphoma cells. J. Immunol., 169, 3202–8.
   Google Scholar
• Lamb L. S., Henslee-Downey P. J., Parrish R. S., Godder K., Thompson J., Lee C. and Gee A. P. (1996) Increased frequency of TCR γ/δ+ T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. J. Hematotherapy, 5, 503–510.
   PubMedGoogle Scholar
• Fisch P., Malkovsky M., Kovats S., Sturm E., Braakman E., Klein B. S., Voss S. D., Morrissey L. W., De Mars R., Welch W. J., Bolhuis R. L. H. and Sondel P. (1990) Recognition by human Vγ9-Vδ2 T cells of a gro-EL homolog on Daudi Burkitt's lymphoma cells. Science, 250, 1269–73.
   PubMed Web of Science ®Google Scholar
• Malkovska V., Cigel F. K., Armstrong N., Storer B. E. and Hong R. (1992) Anti-lymphoma activity of human γδ T cells in mice with severe combined immune deficiency. Cancer Research, 52, 5610–16.
   PubMed Web of Science ®Google Scholar
• Bretscher P. & Cohn M., (1970) A theory of self-nonself discrimination. Science, 169, 1042–9.
   PubMed Web of Science ®Google Scholar
• Dunussi-Jannopoulos K., Weinstein H. J., Nickerson P. W., Strom T. B., Burakoff S. J., Croop J. M. and Arceci R. J. (1996) Irradiated B7–1 transduced primary acute myelogenous leukaemia cells can be used as therapeutic vaccines in murine AML. Blood, 87, 2938–2946.
   PubMed Web of Science ®Google Scholar
• Chen L., Ashe S., Brady W. A., Hellstrom I., Hellstrom K. E., Ledbetter J. A., McGowan P. and Linsley P. S. (1992) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell, 71, 1093–1102.
   PubMed Web of Science ®Google Scholar
• Townsend S. E. and Allison J. P. (1993) Tumor rejection after direct costimulation of CD8 + T cells by B7-transfected melanoma cells. Science, 259, 310–11.
   PubMed Web of Science ®Google Scholar
• Anderson R., Macdonald I., Lowdell M. W., Corbett T., Panayiotidis P., Hart S., Ray N. and Prentice H. G. Construction and characterisation of an Interleukin-12 fusion protein. Human Gene Therapy-in press.
   Google Scholar
• Sivasubramanian B. (1996) Gene-modified tumor cells as cellular vaccine. Cancer Immunol. Immunther., 43, 165–73.
   PubMed Web of Science ®Google Scholar
• Shurin M.R. (1996) Dendritic cells presenting tumor antigen. Cancer Immunol. Immunther., 43, 158–64.
   PubMed Web of Science ®Google Scholar